Single-Pill Low-Dose Triple Combination Therapy vs Standard-Dose Monotherapy in Patients With Mild-to-Moderate...

Area of Science:

• Cardiovascular Medicine
• Clinical Pharmacology
• Hypertension Research

Background:

• Single-pill low-dose combination (LDC) therapy is an emerging strategy for improving blood pressure (BP) control.
• Phase III trials are crucial for validating new antihypertensive treatments.

Purpose of the Study:

• To compare a single-pill ultra-low-dose triple combination (LDC-ALC) with standard-dose monotherapy for hypertension.
• To evaluate the efficacy and safety of LDC-ALC against amlodipine and losartan.

Main Methods:

• Two multicenter, randomized, double-blind, active-controlled phase III studies (HM-APOLLO-301 and HM-APOLLO-302) were conducted in South Korea.
• Adults with mild-to-moderate hypertension were randomized to 8 weeks of treatment with LDC-ALC, amlodipine, or losartan.
• The primary endpoint was systolic blood pressure (SBP) reduction at week 8, assessed for noninferiority and superiority.

Main Results:

• LDC-ALC showed noninferiority to amlodipine in SBP reduction and similar efficacy in Study 301.
• In Study 302, LDC-ALC was noninferior and superior to losartan in SBP reduction, with greater diastolic blood pressure (DBP) reduction.
• Adverse events were similar across groups, with low treatment withdrawal rates and no serious drug-related events.

Conclusions:

• Single-pill LDC-ALC achieved comparable BP reductions to amlodipine and greater reductions than losartan monotherapy.
• LDC-ALC is a well-tolerated and effective alternative initial therapy for mild-to-moderate hypertension.
• These findings support LDC-ALC as a validated strategy alongside established monotherapies.